Description
Introduction Part I. The Journey from Idea to Approval Chapter 1. Leukemia and Lymphoma Chapter 2. Chimeric Antigen Receptor (CAR)-T Cell Therapy Chapter 3. Spinal Muscular Atrophy Chapter 4. In Vivo Gene Therapy Chapter 5. Sickle Cell Anemia Chapter 6. Ex Vivo Gene-Modified Cell Therapy Chapter 7. A Brief History of FDA Regulation Chapter 8. The Path to Approval Part II. Enabling the Next Wave Of Innovation Chapter 9. Building Blocks Chapter 10. Recognizing Value Chapter 11. Financial and Human Capital Investments in Biotechnology Chapter 12. Looking Forward Epilogue. COVID-19 Acknowledgments References Index
Raju Prasad, PhD (CHICAGO, IL), is a partner and biotechnology analyst at William Blair, focusing on cell therapy, gene therapy, and gene editing. Dr. Prasad previously worked as a research associate with the University of North Carolina at Chapel Hill's Gillings School of Global Public Health and as an independent consultant with the US Environmental Protection Agency.